Ophthalmology

It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements and fundus examinations.

Nerve cells in the retina were analyzed at the Vienna University of Technology using microelectrodes. According to researchers, the nerve cells demonstrated surprisingly stable behavior, which is good news for retina implants.

This service will provide researchers with tailored animal models that closely mimic human ocular conditions.

The presentation and the moderated Q&A is scheduled for Tuesday, December 3, 2024 in Presentation Room 3 at 1:30 pm ET.

A study found that a simplified artificial circuit, modeled after the brain's neuronal system, can predict network activity and provide insights into how the brain manages short-term memory, with potential implications for novel treatments of eye movement disorders.

Research needed to establish best diagnostic and management strategies for increasingly common condition.

The new PDUFA goal date for NT-501 as treatment for macular telangiectasia type 2 (MacTel) is March 18, 2025.

Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products.

Ian C. Han, MD, shares his thoughts on the value of anecdotal evidence in our winter 2024 editorial.

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora.

The meeting is set to take place from November 8 to 10, 2024 at the Sheraton Times Square Hotel in New York City.

The candidate, FLQ-101, is a once-daily oral/intravenous solution.

Alfredo Sadun, MD, PhD, is the chief of Ophthalmology at the Doheny Eye Institute of UCLA. At this year's AAO meeting held in Chicago, Illinois, he stopped by the Eye Care Network booth to share insights from the symposium "Professional Longevity 2.0: Assessing the Ophthalmologist," which he presented during.

Adam Muzychuck, MD, FRCSC, sat down to discuss his presentation on the defocus curve performance of trifocal IOLs and the outcomes of the near activity vision questionnaire given to patients implanted with the Envy full range of vision IOL at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

New research presented at the American Academy of Ophthalmology’s Cornea Subspecialty Day is part of the part of the 8-year Zoster Eye Disease Study.

According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, improves vision in patients with early-to-moderate cataracts, by penetrating the eye to reduce lens clouding, the main cause for cataracts.

According to data presented this week at the 128th annual meeting of the American Academy of Ophthalmology, being held in Chicago, about three-quarters of medication volume remains in multiuse eye drop bottles tossed in the garbage well before FDA-regulated expiration dates.

Centricity Vision announced new ZEPTOLink enhancements, reducing treatment time by up to 60%. These updates, aimed at improving cataract surgery efficiency and control, will be showcased at the 2024 American Academy of Ophthalmology Annual Meeting in Chicago.

The e-poster came in 2nd place for the August Deutman award at the EURETINA Congress

Ali Erginay, MD, spoke about the important developments in retinal imaging, specifically the Red-Blue-Green (RGB) imaging modalities during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

The retina space continues to see new advancements and clinical trial results, many of which are shared at industry conferences throughout the year.

Alfonso Savastano, MD, PhD spoke about the SING-IMT implant during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Taiji Sakamoto, MD, PhD, spoke about being a board member of EURETINA and his motivations to be a part of the cooperative work that is a hallmark of EURETINA. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.